Analysis of Clinical Application of China's First Batch of TYRX Absorbable Antibacterial Envelope

Launched by SUN YAT-SEN MEMORIAL HOSPITAL OF SUN YAT-SEN UNIVERSITY · Nov 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a new product called the TYRX absorbable antibacterial envelope in preventing infections related to certain medical devices, known as Cardiac Implantable Electronic Devices (CIEDs). This is the first time this envelope is being used in China, and the trial aims to gather real-world information about how well it works in keeping patients safe from infections after their device implantations.

To be eligible for this trial, patients must be between the ages of 65 and 74 and have received the TYRX envelope at the participating hospital between December 2023 and September 2024. However, if someone has allergies to the materials in the envelope or certain antibiotics, has an existing infection at the implant site, is pregnant or breastfeeding, or is a child or teenager, they cannot participate. Those who are part of the trial can expect to have their health monitored after the envelope is implanted to see how well it helps prevent infections, providing important information for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients who received the TYRX absorbable antimicrobial envelopes at our hospital from December 2023 to September 2024
• Exclusion Criteria:
• • Allergies to the envelope materials or antimicrobial drugs (minocycline and other tetracyclines, rifampin)
• • Existing infections at the CIED implantation site
• • Pregnant or breastfeeding women
• • children and adolescents